TransCode Therapeutics

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Newton, MA.

Study provides additional support for further advancement of TTX-RIGA Study provides additional support for further advancement of TTX-RIGA

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

BOSTON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced today that it has received written authorization from the U.S. Food and Drug Administration (FDA) that it may proceed with its First-in-Human (FIH) Phase 0 clinical trial. The planned clinical trial is to evaluate TransCode's lead therapeutic candidate, TTX-MC138, in up to 12 cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode believes that TTX-MC138 could be used as a treatment for many of these cancers.

TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

TransCode Therapeutics (NASDAQ: RNAZ ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won't pursue a plan to sell 12.5 million shares in a public offering.

Why Is TransCode Therapeutics (RNAZ) Stock Up 148% Today?

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it withdrew the Registration Statement on Form S-1 it filed with the U.S. Securities and Exchange Commission on November 28, 2022, and amended on November 30, 2022. The withdrawal reflects the Company's belief that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company's stockholders.

TransCode Therapeutics Announces Withdrawal of Registration Statement

BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it has submitted an exploratory Investigational New Drug (eIND) application to the U.S. Food and Drug Administration (FDA) for a planned First-in-Human Phase 0 clinical trial. The planned clinical trial is to evaluate TransCode's lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode believes that TTX-MC138 could be used as a treatment for many of these cancers.

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2022, and recent business progress.

TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1, in pancreatic adenocarcinoma.

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it will be presenting at the Sidoti Virtual Conference. TransCode's Chief Executive Officer, Michael Dudley, will describe the company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company's lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its first-in-human clinical trial.  The presentation will be webcast and an archived recording will be made available in the Investors' section of the TransCode Therapeutics website.

TransCode Therapeutics to Present at Sidoti Virtual Investor Conference

It is truly a monumental day for TransCode Therapeutics (NASDAQ: RNAZ ) stock. That's because the company just disclosed the preclinical results of its proposed treatment for pancreatic cancer.

Why Is TransCode Therapeutics (RNAZ) Stock Up 30% Today?

Study provides additional support for further evaluation of TransCode's lead therapeutic candidate, TTX-MC138, in clinical trials Study provides additional support for further evaluation of TransCode's lead therapeutic candidate, TTX-MC138, in clinical trials

TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma

Boston, Massachusetts--(Newsfile Corp. - October 19, 2022) - TransCode Therapeutics (NASDAQ: RNAZ), the RNA Oncology company committed to more effectively treating cancer using RNA therapeutics, will be participating in The ThinkEquity Conference, which will take place on October 26, 2022 at The Mandarin Oriental Hotel in New York. Michael Dudley- CEO/ Co-Founder- will be presenting at 2:30 PM ET on October 26th. Interested parties can register to attend here.

TransCode Therapeutics: Invitation to The ThinkEquity Conference

Study provides support for further evaluation of TransCode's lead therapeutic candidate, TTX-MC138, in clinical trials Study provides support for further evaluation of TransCode's lead therapeutic candidate, TTX-MC138, in clinical trials

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology

Lazydays

Protara Therapeutics Inc

TRACON Pharmaceuticals

Mountain Crest Acquisition Corp II

L. B. Foster

LINKBANCORP Inc

Liquidia Technologies Inc

Larimar Therapeutics Inc

Macerich

MFA Financial

B. Riley Financial

Tilly's

Zivo Bioscience

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it will be presenting at the Chardan 6th Annual Genetic Medicines Conference. TransCode's Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company's lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its First in Human clinical trial planned to begin this year.  The presentation will be webcast and an archived recording will be made available in the Investors' section of the TransCode Therapeutics website.

TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference

BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J. Slack, PhD, to its advisory board.

TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the second quarter ended June 30, 2022, and recent business progress.

TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update

BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson Cancer Center (“MD Anderson”), today announced a strategic alliance to advance TransCode's pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.

TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its intellectual property portfolio through the filing of a provisional patent application (US 63/356,449) entitled RADIOLABELED NANOPARTICLES AND TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY (the ‘449 application). TransCode expects to convert the ‘449 application into an international application in approximately one year.

TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio

BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June 13-16 in San Diego, CA. The in-person venue for the event is the San Diego Convention Center.

TransCode Therapeutics to Participate at BIO International Convention

Funding is part of a 2021 Fast-Track Small Business Innovation Research (SBIR) grant to Support Clinical Development of First-in-Class Therapy for Advanced Solid Tumors

TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award

BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue for the hybrid event is the Fontainebleau Hotel in Miami Beach at 4441 Collins Avenue. Virtual participation will be staged simultaneously as a live feed and available on-demand.

TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference

BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.

TransCode Therapeutics Acquires Option for Radiotheranostic Technology

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for the first quarter ended March 31, 2022, and recent business progress.

TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update

Dr. Medarova will present at the 3rd Annual RNAi-Based Therapeutics Summit on April 20 Dr. Medarova will present at the 3rd Annual RNAi-Based Therapeutics Summit on April 20

TransCode Therapeutics' CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium

TransCode Therapeutics, Inc. (RNAZ) CEO Michael Dudley on Q4 2021 Results - Earnings Call Transcript

News for TransCode Therapeutics Stock (RNAZ)